The clock is ticking. Two weeks later, millions of Americans can lose access to cheap drugs that will help you to lose weight and health.
I need to know -I am one of them.
At the end of his executive, Biden’s Food Pharmacy quietly ended the “tribe” of Tirzepatide, a popular GLP-1 drug.
In other words, on March 19, safe and inexpensive alternatives will be removed from the market and Big Pharma’s interests will soar.
This crisis is worth the agenda when Dr. Marty Macari, who was named Trump’s FDA member, attended the Confirmation hearing before the Senate Health, Education, Labor and Pension Committee.
How can this decision harm Americans because it sounds like a good thing to end the tribe?
First, I understand that Biden’s unilateral law had no effect on changing reality. There is still a shortage of Tirzepatide, which has been popular over the past two years.
But without the government’s recognition of the fact, pharmacies can no longer sell a compound version of the drug, and the cost will increase for consumers.
Today, patients who can combine drugs for $ 350 a month have no choice to pay $ 1,000 a month for Mounjaro or Zepbound.
In short, Tirzepatide will not be inexpensive overnight for many people who rely on it.
GLP-1 drugs such as Tirzepatide (one of some drugs that can help patients are full and less eaten by imitating natural GLP-1 hormones) have become the cornerstone of health care for millions of Americans.
When used under the management of doctors and paired with changes in lifestyles, these drugs revolutionized for weight loss and chronic treatment.
Believe in me, I speak in a personal experience.
Over the years, I tried all weight loss drugs, from Fen-Phen to Contrave and QSYMIA, but GLP-1 was truly a game change.
The end of the Tirzepatide “Shortage” is not separated. In February, FDA’s BIDEN administration holdover declared the end of the lack of other GLP-1 drugs such as Ozempic and WEGOVY.
Increasing access to drugs that change life should be the government’s priority. So why did the BIDEN administration gain a big interest in the welfare of millions of Americans?
The decision to sell us in Biden has a big impact. More than 12% of American adults used GLP-1 drugs to manage chronic diseases, including diabetes, heart disease and obesity.
It will be fatal to those who depend three times the cost of their costs.
Many people who use GLP-1 are at risk of serious cardiovascular and metabolic diseases without drugs. However, insurance companies only pay for the limited situations.
This allows the patient to pay a huge cost. Many people without safe alternatives should be forbidden to create a brand version except for legitimate complex pharmacies.
In fact, according to recent data, millions of Americans can turn into un regulated sources instead if the Tir prepared tide is not cheap.
According to an internal poll conducted by IVIM HEALTH, 85%of GLP-1 users will turn into an alternative to the drug if the price is huge.
And Americans will compromise health, but big constraints will continue to benefit.
The United States is in a crisis. By eliminating cheap accessibility to innovative treatment, we can miss the opportunity to reduce the risks of heart disease, diabetes, hypertension, respiratory disorders, etc.
Studies have shown that if the drug is suddenly removed, the patient due to the GLP-1 therapy will increase the risk of weight recovery, heart attack, stroke and other major cardiovascular events due to the rush of the FDA.
Americans cannot endure and tolerate our government, which sacrifices our health and prioritizes corporate interests.
And this is just about one kind of drug. The FDA continued to show the reality so that the company’s interests can take advantage of our health care.
President Trump’s FDA must modify the process. On March 19, Americans will pay for the price without urgent action.
Sean Spicer, who worked as the 30th White House reporter, hosts Sean Spicer Show Podcast.
